BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Semaglutide (Wegovy) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Semaglutide (Wegovy)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05195944-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT05195944)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, MASH / NASH.\nStudy: Semagluti
 de vs Sitagliptin\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05195944
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05173714-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT05173714)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Sit Less\, In
 teract and Move More (SLIMM) 2 Study\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semagluti
 de-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05173714
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07057310-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07057310)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Aging Well: T
 argeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Heal
 th in Postmenopausal Women\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0705
 7310
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06825793-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT06825793)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: Semaglutide'
 s Weight Loss Effects in Obesity\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-w
 egovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06825793
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989203-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT06989203)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: Protein Supp
 lementation Intervention on Body Weight\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semagl
 utide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06989203
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06546384-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT06546384)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: GLP-1 RA on 
 Alcohol Consumption\, Metabolism and Liver Parameters in Patients With Obe
 sity and Fatty Liver Disease\nEstimated primary completion: 31 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegov
 y#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 546384
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04174755-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT04174755)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: Semaglutide'
 s Efficacy in Achieving Weight Loss for Those With HIV\nEstimated primary 
 completion: January 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04174755
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05202353-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:Semaglutide (Wegovy): Phase 1 readout est. (NCT05202353)
DESCRIPTION:Semaglutide (Wegovy)\, phase 1\, Obesity.\nStudy: A Study in Pe
 ople With Obesity to Test the Effects of BI 456906 Compared With Semagluti
 de on Glucagon Receptor Activity in the Liver\nEstimated primary completio
 n: 6 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/se
 maglutide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05202353
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282769-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07282769)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2.\nStudy: Semaglutide (Wegovy) Tr
 eatment for Trichotillomania\nEstimated primary completion: February 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07282
 769
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242534-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07242534)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Effect of Sem
 aglutide on Embryo Quality in Overweight and Obese Patients Undergoing In 
 Vitro Fertilization.\nEstimated primary completion: February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07242534
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840729-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Semaglutide (Wegovy): Phase 1 readout est. (NCT07840729)
DESCRIPTION:Semaglutide (Wegovy)\, phase 1\, Obesity.\nStudy: Evaluate the 
 Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Par
 ticipants\nEstimated primary completion: 28 February 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07840729
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101939-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07101939)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: A Study of th
 e Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in O
 bese Patents During (PROACT 1)\, and Post-semaglutide Therapy (PROACT 2)\n
 Estimated primary completion: March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07101939
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293325-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270402
DTEND;VALUE=DATE:20270403
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT07293325)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: Semaglutide 
 and Tirzepatide for Genetic Aging Delay in Adults With Obesity\nEstimated 
 primary completion: 2 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07293325
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854614-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT06854614)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Sequential Th
 erapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and
  MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)\nE
 stimated primary completion: 28 April 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06854614
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07411378-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07411378)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Testing the E
 fficacy\, Safety\, and PK of 20E in Patients With Obesity Who Are Starting
  Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.\nEstimated 
 primary completion: June 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07411378
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639021-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07639021)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: A Research St
 udy Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Par
 ticipants With Obesity\nEstimated primary completion: 14 June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07639021
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06803888-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT06803888)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Bariatric Sur
 gery vs. Semaglutide vs. Tirzepatide\nEstimated primary completion: 1 July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-we
 govy#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06803888
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754163-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT06754163)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Evaluating th
 e Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Meas
 ures of Atypical Antipsychotic-Treated Patients\nEstimated primary complet
 ion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/se
 maglutide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06754163
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136714-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07136714)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Does Semaglut
 ide Improve Depressive Symptoms in Patients With Major Depressive Disorder
  and Overweight or Obesity\nEstimated primary completion: September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071367
 14
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06575738-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Semaglutide (Wegovy): Phase 1 readout est. (NCT06575738)
DESCRIPTION:Semaglutide (Wegovy)\, phase 1\, Obesity.\nStudy: Physiologic R
 esponse to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adol
 escents\nEstimated primary completion: 1 September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06575738
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845578-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270911
DTEND;VALUE=DATE:20270912
SUMMARY:Semaglutide (Wegovy): Phase 1 readout est. (NCT07845578)
DESCRIPTION:Semaglutide (Wegovy)\, phase 1\, Obesity.\nStudy: A Research St
 udy Looking Into How a High Dose of s.c. Semaglutide Works With Emptying o
 f the Stomach in People With Excess Body Weight\nEstimated primary complet
 ion: 11 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07845578
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497595-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT06497595)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: Lifestyle In
 tervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obes
 ity Treated With Semaglutide\nEstimated primary completion: 30 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wego
 vy#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6497595
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06499857-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT06499857)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Semaglutide f
 or Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation\nE
 stimated primary completion: December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06499857
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06814938-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT06814938)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: A Study of a 
 Novel Precision Medicine Approach For Obesity\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sem
 aglutide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06814938
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05746039-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Semaglutide (Wegovy): Phase 1/2 readout est. (NCT05746039)
DESCRIPTION:Semaglutide (Wegovy)\, phase 1/2\, Obesity.\nStudy: Feasibility
  of Semaglutide in Advanced Lung Disease\nEstimated primary completion: 28
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semag
 lutide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05746039
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423599-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Semaglutide (Wegovy): Phase 2/3 readout est. (NCT06423599)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2/3\, Obesity.\nStudy: Effect of W
 eight Loss on Physical and Cardiac Performance in People With Obesity and 
 Heart Failure\nEstimated primary completion: 30 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06423599
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07783854-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07783854)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: A Randomized 
 Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss M
 aintenance in Adults With Overweight or Obesity\nEstimated primary complet
 ion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07783854
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06852391-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT06852391)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: JOULE - Metab
 olic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Prog
 ram With or Without Semaglutide in Adolescents With Obesity\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06852391
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07779343-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280123
DTEND;VALUE=DATE:20280124
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT07779343)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: OBESIAL: A P
 rospective Interventional Real-world Study of a Multidisciplinary Obesity 
 Management Programme\nEstimated primary completion: 23 January 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07779343
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06801015-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT06801015)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Effects of Lo
 ng-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP 
 [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Fu
 nctions\nEstimated primary completion: 31 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06801015
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621640-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT07621640)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: Brown Adipos
 e Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in
  Obesity (BAT-Sema Study)\nEstimated primary completion: February 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07621640
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213466-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07213466)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Individualize
 d Pharmacological Approach to Obesity in Patients With Bipolar Disorder\nE
 stimated primary completion: 1 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07213466
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07732426-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT07732426)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: Effects of S
 emaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity
  and Food Addiction Tendencies\nEstimated primary completion: 29 February 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-weg
 ovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07732426
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859176-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07859176)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Tapered Versu
 s Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weigh
 t Gain or Suboptimal Response Following Metabolic and Bariatric Surgery\nE
 stimated primary completion: April 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07859176
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527195-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Semaglutide (Wegovy): Phase 1 readout est. (NCT07527195)
DESCRIPTION:Semaglutide (Wegovy)\, phase 1\, Obesity.\nStudy: Understanding
  the Effect of CagriSema\, Cagrilintide\, and Semaglutide on Muscle Health
  (Role of Amylin Signature in Muscle Health)\nEstimated primary completion
 : 28 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sema
 glutide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07527195
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07727473-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Semaglutide (Wegovy): Phase 1 readout est. (NCT07727473)
DESCRIPTION:Semaglutide (Wegovy)\, phase 1.\nStudy: Preoperative Semaglutid
 e Prior to Radical Prostatectomy\nEstimated primary completion: May 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077274
 73
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633639-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT07633639)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: GLP-1 Therap
 y After Bariatric Surgery in Chinese Patients With Obesity\nEstimated prim
 ary completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07633639
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010432-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280503
DTEND;VALUE=DATE:20280504
SUMMARY:Semaglutide (Wegovy): Phase 1 readout est. (NCT07010432)
DESCRIPTION:Semaglutide (Wegovy)\, phase 1\, Obesity.\nStudy: The Role of t
 he Amylin Analogue Cagrilintide in Bone Metabolism\nEstimated primary comp
 letion: 3 May 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 emaglutide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07010432
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06173778-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280525
DTEND;VALUE=DATE:20280526
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT06173778)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Semaglutide f
 or Post-Smoking Cessation Weight Management\nEstimated primary completion:
  25 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglu
 tide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06173778
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909006-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT06909006)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Semaglutide T
 reatment in Type 1 Diabetes\nEstimated primary completion: June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06909006
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03884075-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT03884075)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, MASH / NASH.\nStudy: Non-Alcoh
 olic Fatty Liver Disease\, the HEpatic Response to Oral Glucose\, and the 
 Effect of Semaglutide (NAFLD HEROES)\nEstimated primary completion: 31 Aug
 ust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide
 -wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03884075
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294950-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07294950)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Impact of Sem
 aglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Ba
 lance: Recovery Effects After Semaglutide Termination\nEstimated primary c
 ompletion: September 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07294950
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770152-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07770152)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Semaglutide i
 n Youth With Autism Spectrum Disorder\nEstimated primary completion: 1 Sep
 tember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglut
 ide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07770152
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855133-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280906
DTEND;VALUE=DATE:20280907
SUMMARY:Semaglutide (Wegovy): Phase 1 readout est. (NCT07855133)
DESCRIPTION:Semaglutide (Wegovy)\, phase 1\, Obesity.\nStudy: A Research St
 udy Investigating How Adults With Overweight or Obesity\, With or Without 
 Type 2 Diabetes\, Tolerate Switching to a New Treatment (Zenagamtide) From
  Their Current Semaglutide Medication\nEstimated primary completion: 6 Sep
 tember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglut
 ide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07855133
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589322-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT07589322)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: Comparative 
 Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhance
 d Incretin AgonisTs\nEstimated primary completion: 30 September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07589322
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859189-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07859189)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Immediate Ver
 sus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Y
 ear After Primary Metabolic and Bariatric Surgery\nEstimated primary compl
 etion: October 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 semaglutide-wegovy#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07859189
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859137-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07859137)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Semaglutide B
 efore Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m
 ² or Higher\nEstimated primary completion: November 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07859137
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06571383-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT06571383)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: STEP TEENS We
 ight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers
  With Excess Body Weight to Lose Weight and Maintain Weight Loss\nEstimate
 d primary completion: 15 November 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06571383
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07870538-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07870538)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: A Neuropsycho
 biological Approach to Optimize Patient Selection for GLP-1-based Pharmaco
 therapy for Weight Management Across the Binge Eating Spectrum\nEstimated 
 primary completion: December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07870538
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07592546-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07592546)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Translational
  Health Research Into Vascular and Neurocognitive Effects of Weight Loss\n
 Estimated primary completion: 1 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07592546
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07275697-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07275697)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Waiting on At
 rial Fibrillation Intervention Therapy (WAIT) Study\nEstimated primary com
 pletion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07275697
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07820358-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07820358)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Semaglutide\,
  Weight Loss\, and LNG-IUD for Conservative Treatment of Endometrial Atypi
 cal Hyperplasia and Grade 1 Endometrial Cancer\nEstimated primary completi
 on: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /semaglutide-wegovy#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07820358
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07858331-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07858331)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Patient-centr
 ed Intervention With Virtual Support for Obesity and Kidney Transplant Acc
 ess\nEstimated primary completion: 1 January 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07858331
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06073184-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT06073184)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2.\nStudy: Weight-loss Drug for Fe
 rtility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of 
 the Endometrium\nEstimated primary completion: February 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06073184
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07909889-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07909889)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Semaglutide f
 or Weight Management During Hormone Therapy for Early Breast Cancer\nEstim
 ated primary completion: March 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07909889
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859150-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07859150)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Semaglutide 2
 .4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric 
 Surgery (RESURGE)\nEstimated primary completion: April 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07859150
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859163-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07859163)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Semaglutide G
 iven Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastri
 c Bypass for Recurrent Weight Gain\nEstimated primary completion: April 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegov
 y#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 859163
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04822181-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290425
DTEND;VALUE=DATE:20290426
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT04822181)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, MASH / NASH.\nStudy: Research 
 Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepa
 titis (NASH)\nEstimated primary completion: 25 April 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04822181
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946796-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07946796)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Semaglutide E
 ffects on Sperm Concentration in Overweight Infertile Men\nEstimated prima
 ry completion: June 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07946796
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06913023-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Semaglutide (Wegovy): Phase 2/3 readout est. (NCT06913023)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2/3.\nStudy: Semaglutide for the P
 revention Of Post-Transplant Diabetes Mellitus\nEstimated primary completi
 on: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sem
 aglutide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06913023
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06885736-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20290830
DTEND;VALUE=DATE:20290831
SUMMARY:Semaglutide (Wegovy): Phase na readout est. (NCT06885736)
DESCRIPTION:Semaglutide (Wegovy)\, phase na\, Obesity.\nStudy: LEAN Mass Pr
 eservation With Resistance Exercise and Protein During Semaglutide/Tirzepa
 tide Therapy\nEstimated primary completion: 30 August 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06885736
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900074-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07900074)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Mechanisms of
  Weight Loss: Tirzepatide vs Semaglutide\nEstimated primary completion: 31
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semag
 lutide-wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07900074
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253285-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20300320
DTEND;VALUE=DATE:20300321
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07253285)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: A Research St
 udy on How Well Cagrilintide and CagriSema Work in Children and Adolescent
 s With Excess Body Weight\nEstimated primary completion: 20 March 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07253285
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07872904-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07872904)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: FutureShape F
 amily\nEstimated primary completion: 31 May 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07872904
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797036-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Semaglutide (Wegovy): Phase 2/3 readout est. (NCT07797036)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2/3.\nStudy: Postpartum Semaglutid
 e to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus\nEsti
 mated primary completion: 1 September 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07797036
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07090343-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07090343)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3.\nStudy: Semaglutide in Patients
  Undergoing Transcatether Aortic Valve Replacement\nEstimated primary comp
 letion: 1 September 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07090343
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934655-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT06934655)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Early Reiniti
 ation of Semaglutide Post-Sleeve Gastrectomy in Youth\nEstimated primary c
 ompletion: 1 November 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06934655
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07731256-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Semaglutide (Wegovy): Phase 2 readout est. (NCT07731256)
DESCRIPTION:Semaglutide (Wegovy)\, phase 2\, Obesity.\nStudy: Semaglutide f
 or Low Back Pain\nEstimated primary completion: 1 January 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07731256
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06977438-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT06977438)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: GLP-1 Plus Li
 festyle for Overall Wellness: Find Your Way Forward\nEstimated primary com
 pletion: 31 January 2031. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06977438
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845994-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07845994)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: SEMAFORCRANIO
  : Multicenter\, Double-blind\, Parallel\, Randomized Controlled Trial of 
 the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopha
 ryngioma in Children Aged 12 to 17 Years\nEstimated primary completion: Ma
 rch 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglutide
 -wegovy#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07845994
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07021937-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07021937)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Brain Plastic
 ity and GLP-1 Receptor Agonist Treatment for Obesity\nEstimated primary co
 mpletion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/semaglutide-wegovy#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07021937
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07769047-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20310730
DTEND;VALUE=DATE:20310731
SUMMARY:Semaglutide (Wegovy): Phase 4 readout est. (NCT07769047)
DESCRIPTION:Semaglutide (Wegovy)\, phase 4\, Obesity.\nStudy: Semaglutide a
 nd Structured Lifestyle Support to Improve Heart and Blood Vessel Health i
 n Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors
 \nEstimated primary completion: 30 July 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07769047
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949474-11054@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Semaglutide (Wegovy): Phase 3 readout est. (NCT07949474)
DESCRIPTION:Semaglutide (Wegovy)\, phase 3\, Obesity.\nStudy: Semaglutide i
 n Alcohol Use Disorder\nEstimated primary completion: 30 April 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07949474
URL:https://assetmemo.bio/drug/semaglutide-wegovy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
